相关实验视频

Updated: Jul 7, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

对于ALS新药试验的优点?

Ettore Beghi, Caterina Bendotti, Tiziana Mennini

    Science (New York, N.Y.)
    |May 3, 2005
    PubMed
    概括

    No abstract available in PubMed .

    更多相关视频

    Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
    12:35

    Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

    Published on: March 17, 2012

    Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
    04:41

    Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

    Published on: February 24, 2026

    相关实验视频

    Last Updated: Jul 7, 2026

    ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
    15:48

    ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

    Published on: July 29, 2007

    Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
    12:35

    Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

    Published on: March 17, 2012

    Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
    04:41

    Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

    Published on: February 24, 2026

    相关概念视频

    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    JoVE
    关于 JoVE
    概览领导团队博客JoVE 帮助中心
    作者
    出版流程编辑委员会范围与政策同行评审常见问题投稿
    图书馆员
    用户评价订阅访问资源图书馆顾问委员会常见问题
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
    使用条款与条件
    隐私政策
    政策
    Jove
    Visualize
    联系我们